Epigenetic silencing of ID4 may drive stemness and resistant prostate cancer
Official title: Epigenetic Silencing of Inhibitor of Differentiation 4 (ID4) Promotes Stem Cell and Castration Resistant Phenotype in Prostate Cancer
Funded at Clark Atlanta University · NIH-11325046 · Data updated 2026-11-12
A cancer research grant explores how turning off a protective gene (ID4) could make prostate cancer more stem-like and resistant to therapy, with potential patient impact.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clark Atlanta University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 1, 1997 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $188,288 |
| NIH project number | 5U54MD007590-39 |
| Project ID | NIH-11325046 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with prostate cancer, particularly those with aggressive or treatment-resistant disease, may benefit from advances arising from this research.
✕Less likely to help
Individuals without prostate cancer or those not affected by AR/ID4-related pathways are unlikely to benefit directly.
What this research studies
This project looks at how loss of ID4 changes prostate cancer biology and makes tumors more aggressive, especially after hormone therapies. Researchers use cell and animal models to study how ID4 loss changes androgen receptor behavior and stem-cell features in prostate cancer. The goal is to identify new targets to prevent or treat castration-resistant prostate cancer that often resists current treatments.
Why it matters
Potential benefit: If successful, findings could lead to new approaches to prevent or treat therapy-resistant prostate cancer.
How similar studies have gone: Prior work shows ID4 loss is linked to more aggressive prostate cancer and stem-cell features, suggesting this approach is promising but still under investigation.
Where this research is happening
-
Clark Atlanta University
Atlanta, United States Active
Researchers
- Principal investigator: Chaudhary, Jaideep — Clark Atlanta University
- Study coordinator: Chaudhary, Jaideep
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.